Am J Transplant, Volume 19, Suppl 3 Archives - Page 179 of 214 - ATC Abstracts

2019 American Transplant Congress
Predicting Post-Transplant Graft Function in Deceased Donor Kidney Transplant Recipients
K. Archer¹, Y. Zhang¹, V. Bontha², J. Eason³, L. Gallon⁴, E. Akalin⁵, D. Maluf², V. Mas²
¹OSU, Columbus, OH, ²UTHSC, Memphis, TN, ³UTHSC Director of Transplant Institute, Memphis, TN, ⁴NWU, Chicago, IL, ⁵Albert Einstein College of Medicine, NYC, NY
*Purpose: Discarding donor organs lengthens time patients spend on the kidney transplant (KT) wait list. To identify characteristics associated with short-term outcome in deceased donor…
2019 American Transplant Congress
Liquid Biopsy for Chronic Rejection after Kidney Transplantation. A Novel Non-Invasive Biomarker Involved in Inflammatory Amplifier
Y. Takada¹, D. Kamimura², H. Higuchi¹, D. Iwami¹, K. Hotta¹, N. Iwahara¹, N. Shinohara¹, M. Murakami²
¹Renal and Genitourinary Surgery, Hokkaido University Hospital, Sapporo, Japan, ²Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
*Purpose: In kidney transplantation (KTx), despite recent advances of medical technology, chronic rejection accounts for 25% of the graft loss. Chronic active antibody-mediated rejection (CAAMR)…
2019 American Transplant Congress
Evaluation of Delayed Renal Allograft Function after DCD with New Biomarkers in Donor Blood
X. Zheng
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
*Purpose: To explore the relationship between new biomarkers in donor blood and delayed graft function (DGF) after DCD kidney transplantation, and to evaluate the clinical…
2019 American Transplant Congress
HIV Resistance among HOPE Donor Referrals
B. Barnaba¹, W. Werbel¹, O. Kusemiju¹, C. Kirby¹, Y. Eby¹, R. Fernandez¹, J. Miller¹, A. Redd², D. Segev¹, A. Tobian¹, C. Durand¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD
*Purpose: After success in South Africa, HIV+ deceased donor (HIV D+) organs can now be used for transplant to HIV+ recipients in the US under…
2019 American Transplant Congress
Estimated Post Transplant Survival Allocation: Not Just Better Kidneys, but Faster Ones as Well
L. Ormiston¹, G. Vranic², J. Moore², B. Thomas², M. Cooper², A. Gilbert²
¹Georgetown University School of Medicine, Washington, DC, ²Medstar Georgetown Transplant Institute, Washington, DC
*Purpose: Since 2014 the Kidney Allocation System (KAS) has used estimated post-transplant survival (EPTS) scores and longevity matching to prioritize patients with the best EPTS…
2019 American Transplant Congress
Donor-Recipient Matching in Kidney Transplant: The Whole is Greater Than the Sum of the Parts
A. Vinson, K. Tennankore, B. Kiberd
Dalhousie University, Halifax, NS, Canada
*Purpose: In deceased donor kidney transplantation, strategic organ allocation is expected to prolong patient and graft survival after transplant. The aim of this study was…
2019 American Transplant Congress
Impact of Induction Choice and Early Steroid Withdrawal on Outcomes in HLA Zero Mismatched Kidney Transplant Recipients
C. Votruba¹, K. Holdener¹, B. Astor², F. Aziz², D. Mandelbrot²
¹Pharmacy, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Nephrology, University of Wisconsin Hospitals and Clinics, Madison, WI
*Purpose: Ideal induction and immunosuppression therapy for 6-antigen HLA matched deceased and living kidney transplant recipients (KTR) is not well understood.*Methods: All 6-antigen HLA matched…
2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…
2019 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation 5 Years Results
Y. Watarai¹, S. Narumi¹, T. Tomosugi¹, M. Okada¹, K. Futamura², M. Tsujita², T. Hiramitsu¹, T. Kobayashi³, N. Goto²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, ²Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³Kidney Transplant Surgery, Aichi Medical University, Nagoya, Japan
*Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…
2019 American Transplant Congress
Monitoring And Management Of Proteinuria Is Often Ignored In Patients Receiving mTOR Therapy Following Orthotopic Liver Transplantation
R. Kaur¹, O. Sadiq², M. Alimirah¹, F. Kumssa¹, A. Patel³, S. Jafri²
¹Internal Medicine, Henry Ford Hospital, Detroit, MI, ²Gastroenterology, Henry Ford Hospital, Detroit, MI, ³Nephrology, Henry Ford Hospital, Detroit, MI
*Purpose: Use of mTOR inhibitors, such as Everolimus (EVL), in liver transplant (LT) patients continues to rise as the side effect profile becomes more evident.…